DK0574313T3 - 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme - Google Patents

1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme

Info

Publication number
DK0574313T3
DK0574313T3 DK93401476T DK93401476T DK0574313T3 DK 0574313 T3 DK0574313 T3 DK 0574313T3 DK 93401476 T DK93401476 T DK 93401476T DK 93401476 T DK93401476 T DK 93401476T DK 0574313 T3 DK0574313 T3 DK 0574313T3
Authority
DK
Denmark
Prior art keywords
treatment
nervous system
central nervous
disubstituted piperazines
neuroendocrine disorders
Prior art date
Application number
DK93401476T
Other languages
English (en)
Inventor
Jean-Louis Peglion
Bertrand Goument
Mark Millan
Jean-Michel Rivet
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Application granted granted Critical
Publication of DK0574313T3 publication Critical patent/DK0574313T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK93401476T 1992-06-12 1993-06-10 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme DK0574313T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR929207065A FR2692264B1 (fr) 1992-06-12 1992-06-12 Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
DK0574313T3 true DK0574313T3 (da) 2000-04-03

Family

ID=9430639

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93401476T DK0574313T3 (da) 1992-06-12 1993-06-10 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme

Country Status (13)

Country Link
US (1) US5464834A (da)
EP (1) EP0574313B1 (da)
JP (1) JP2634370B2 (da)
AT (1) ATE185345T1 (da)
AU (1) AU658512B2 (da)
CA (1) CA2098252A1 (da)
DE (1) DE69326637T2 (da)
DK (1) DK0574313T3 (da)
ES (1) ES2139638T3 (da)
FR (1) FR2692264B1 (da)
GR (1) GR3031492T3 (da)
NZ (1) NZ247854A (da)
ZA (1) ZA934143B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
GB9308725D0 (en) * 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
FR2734819B1 (fr) * 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US6156057A (en) * 1995-08-12 2000-12-05 Fox; James Allan Method for inducing hypothermia
JPH09124643A (ja) * 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
FR2738823B1 (fr) * 1995-09-15 1997-10-31 Synthelabo Derives de 3-(omega-(4-(thieno(3,2-c)pyridin-4-yl)piperazin- 1-yl)alkyl)-3,4-dihydroquinolein-2(1h)-one,leur preparation et leur application en therapeutique
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
US6090132A (en) * 1996-08-15 2000-07-18 Fox; James Allan Method and apparatus for inducing hypothermia
ATE246683T1 (de) * 1996-12-20 2003-08-15 Lundbeck & Co As H Indan- oder dihydroindol-derivate
US6436940B2 (en) 1996-12-20 2002-08-20 H. Lundbeck A/S Indane or dihydroindole derivatives
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2128266B1 (es) 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
AR013206A1 (es) * 1997-07-25 2000-12-13 Lundbeck & Co As H Derivados indol y 2,3-dihidroindol, composiciones farmaceuticas que contienen estos compuestos y el uso de dichos compuestos para la preparacion de un medicamento para el tratamiento de desordenes sensibles a la inhibicion de la reabsorcion de serotonina y antagonismo de receptores 5-ht1a.
AU736596B2 (en) * 1997-07-25 2001-08-02 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
TW530054B (en) * 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
FR2769312B1 (fr) * 1997-10-03 1999-12-03 Adir Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1025097B1 (en) * 1997-10-24 2005-04-27 Neurogen Corporation 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine d 4? receptor subtype ligands
US6040448A (en) 1997-10-24 2000-03-21 Neurogen Corporation Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands
US6177566B1 (en) 1998-06-30 2001-01-23 Neurogen Corporation 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
ATE276249T1 (de) * 1999-12-29 2004-10-15 Pfizer Prod Inc Optisch aktive 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluor methyl)-phenyl)-2-pyrrolidinone als selektive 5-ht1d rezeptor antagonisten
ES2188344B1 (es) * 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
CA2453837C (en) * 2001-07-20 2011-10-04 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder using eltoprazine and related compounds
US20060122177A1 (en) * 2004-12-07 2006-06-08 Solvay Pharmaceuticals B.V. Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US7371769B2 (en) * 2004-12-07 2008-05-13 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US20070072870A2 (en) * 2004-12-08 2007-03-29 Solvay Pharmeceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
JP2008537725A (ja) * 2004-12-08 2008-09-25 ソルベイ・フアーマシユーチカルズ・ベー・ブイ 部分的ドーパミン−ｄ２受容体作動性とセロトニン再摂取阻害の組み合わせを示すフェニルピペラジン誘導体
FR2884251B1 (fr) * 2005-04-08 2007-07-13 Servier Lab Derives de piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2909670B1 (fr) 2006-12-12 2010-07-30 Sanofi Aventis Derive fluore de quinoleine-2(1h)-one,son procede de preparation et son utilisation comme intermediaire de synthese
RU2707067C2 (ru) 2009-12-04 2019-11-22 Суновион Фармасьютикалз, Инк. Полициклические соединения и способы их применения
MA45857A (fr) 2016-07-29 2021-05-19 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
CN116808023A (zh) 2017-02-16 2023-09-29 桑诺维恩药品公司 治疗精神分裂症的方法
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
WO2019029802A1 (en) * 2017-08-09 2019-02-14 Telefonaktiebolaget Lm Ericsson (Publ) SYSTEM AND METHOD FOR SELECTING ANTENNA BEAM
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
IL297248A (en) 2020-04-14 2022-12-01 Sunovion Pharmaceuticals Inc (s)-(5,4-dihydro-7h-thiano[3,2-c]pyran-7-yl)-n-methylmethanamine for the treatment of neurological and psychiatric disorders
CN113896709B (zh) * 2021-11-22 2023-02-28 南京一苇医药科技有限公司 一种苯并噻吩-3-乙酸的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037852C3 (de) * 1970-07-30 1980-06-26 Boehringer Sohn Ingelheim Neue Piperazinderivate und Verfahren zu ihrer Herstellung
US4335126A (en) * 1977-03-10 1982-06-15 Degussa Aktiengesellschaft 1-[3-(3,4,5-Trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine-derivatives having pharmaceutical activity
FR2515647A1 (fr) * 1981-11-03 1983-05-06 Cortial Nouvelles imines derivees de (phenyl-4 piperazinylethyl)-2 anilines, leur methode de preparation et leur application therapeutique
DE3571436D1 (en) * 1984-12-21 1989-08-17 Duphar Int Res New pharmaceutical compositions having anti-psychotic properties
NZ219380A (en) * 1986-02-27 1990-06-26 Duphar Int Res (n-piperidinyl)- and (n-piperazinyl)-methylazole derivatives and pharmaceutical compositions
JPH01113377A (ja) * 1987-10-23 1989-05-02 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
FR2670491B1 (fr) * 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
DE4127849A1 (de) * 1991-08-22 1993-02-25 Merck Patent Gmbh Benzodioxanderivate

Also Published As

Publication number Publication date
DE69326637T2 (de) 2000-05-18
GR3031492T3 (en) 2000-01-31
CA2098252A1 (fr) 1993-12-13
JP2634370B2 (ja) 1997-07-23
US5464834A (en) 1995-11-07
NZ247854A (en) 1994-09-27
ZA934143B (en) 1994-01-17
FR2692264B1 (fr) 1994-08-05
AU4017893A (en) 1993-12-16
EP0574313B1 (fr) 1999-10-06
FR2692264A1 (fr) 1993-12-17
AU658512B2 (en) 1995-04-13
ATE185345T1 (de) 1999-10-15
ES2139638T3 (es) 2000-02-16
JPH06179670A (ja) 1994-06-28
DE69326637D1 (de) 1999-11-11
EP0574313A1 (fr) 1993-12-15

Similar Documents

Publication Publication Date Title
DK0574313T3 (da) 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme
ATE125537T1 (de) 1,4-disubstituierte piperazine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
DE69106365D1 (de) Chinuclidinderivate.
DK0725779T3 (da) Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner
DK164937C (da) Analogifremgangsmaade til fremstilling af 1-alkyl-2-aminotetralinderivater eller farmaceutisk acceptable syreadditionssalte deraf samt 1-alkyl-2-aminotetralinderivater til anvendelse som udgangsmateriale i fremgangsmaaden
NO180632C (no) 1,3-substituerte cykloalkener og cykloalkaner som sentralnervesystem-midler
ATE122042T1 (de) Pyrazoloisoquinoline-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
PT783495E (pt) Derivados de quinoxalina uteis em terapia
ES8304976A1 (es) "procedimiento para la preparacion de derivados triptaminicos sustituidos de tieniloxipropanolaminas, racemicos y opticamente activos".
DK0617027T3 (da) N-benzylpiperazinforbindelser, fremgangsmåde til fremstilling heraf og sammensætninger indeholdende forbindelserne
ATE123776T1 (de) Aminoalkylchromone, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
ATE56705T1 (de) Piperidinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DK0518769T3 (da) Hidtil ukendte ethanolaminbenzoatderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem.
ATE33493T1 (de) Phenylethylaminopropiophenon-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE69320542D1 (de) Pyrrolothienopyrazin-Verbindungen als 5HT3-Rezeptoren-Antagonisten